Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus.

Feray Ferda Şenol; İlkay Bahçeci; Nuray Arslan; Özlem Aytaç; Pinar Öner; Arzu Şenol; Zülal Aşcı Toraman

Research Article

Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus.

Year 2021, Volume: 6 Issue: 2, 90 - 96, 30.06.2021

Feray Ferda Şenol İlkay Bahçeci Nuray Arslan Özlem Aytaç Pinar Öner Arzu Şenol Zülal Aşcı Toraman

Abstract

ABSTRACT
Background: Hepatitis C virus (HCV) infection is one of the important health problems in our country and in the world. While there is no effective vaccine against HCV yet in preventing transmission, there is a protective vaccine against Hepatitis B virus (HBV). Therefore, it is recommended that patients infected with hepatitis C should be screened for hepatitis B and vaccines for prophylactic purposes should be administered to non-infected individuals. In this study, it was aimed to detect seronegative individuals by retrospectively detecting hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (Anti-HBS) seroprevalence and isolated AntiHBc IgG positivity in outpatient and inpatient HCV-infected patients admitted to our hospital.

Material and Method: In this study; Patients diagnosed with chronic hepatitis C who admitted to our hospital between October 2018 and September 2020 were retrospectively analyzed. Patients in whom HBsAg, hepatitis B Anti-HBs and hepatitis B core antibody (Anti-HBc IgG) were investigated, which are among the hepatitis B infection markers, were included in the study.

Results: The 821 patients of study group, 305 (37.15%) were female, 516 patients (62.85%) were male and with a mean age of 47 ± 11.5. Accompanying HBsAg was positive in 17 (2.07%) patients, Anti-HBs positivity in 231 (28.13%) patients, and isolated Anti-HBc Ig G seropositivity in 75 (9.13%) patients.

Conclusion:HBsAg, Anti-HBs positivity, isolated Anti-HBc IgG seropositivity in patients with chronic HCV were found to be similar to national and national data. In line with these results, it was concluded that every patient diagnosed with HCV should be screened for HBV serology and that seronegative people should be included in the vaccination program in order to prevent the development of HBV coinfection.

Keywords

AntiHBV, HBV, HCV

Supporting Institution

Project Number

Thanks

References

1. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59 (3):18-27.
2. Dilek AR, Sahin K, Bahceci I, Dilek N. The different distribution of hepatitis C virus genotypes in Eastern Black Sea region of Turkey - J Microb Biochem Technol, 2013;5 (4):92-4
3. World Health Organization (WHO). Global hepatitis report 2017-WHO 2018.
4. Degenhardt L, Peacock A, Colledge S, Leung J, Vickerman P, Stone J, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal 2017; 5(12): e1192-e1207.
5. Bahçeci I, Yıldız I. HIV Seropositivity in Patients Admitted to Our Hospital: Six Year Evaluation. Duzce Medical Journal. 2021; 23(1): 25-29.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007; 132 (7): 2557-76.
7. Shepard CW, Finelli L, Alter MJ .Global epidemiology of hepatitis C virus infections. Lancet Infect Dis, 2005; 5 (9): 558 -67.
8. Sünbül M. HCV İnfeksiyonunun Epidemiyolojisi ve Korunma. Ed : Tabak F,Balık İ, Tekeli E. Viral Hepatit 2007. 1st ed. İstanbul Tıp Kitabevi, 2007: 208-19.
9. Taşyaran MA. Hepatit B virüs infeksiyonunda klinik.Viral Hepatit 2007’de. Ed. Tabak F, Tekeli E, Balık İ. 1.Baskı. İstanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;118-22.
10. Özdemir D, Kurt H. Hepatit B virüsü enfeksiyonlarının epidemiyolojisi. Viral Hepatit 2007’de. Ed. Tabak F, Tekeli E,Balık İ. 1. baskı. istanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;108-7.
11. Mıstık R. Türkiye’de viral hepatit epidemiyolojisi yayınlarının irdelenmesi. Viral Hepatit 2007’de. Ed. Tabak F, Balık İ, Tekeli E. 1.baskı. istanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;10-50.
12. Global hepatit raporu. Cenevre: Dünya Sağlık Örgütü. Erişim: http://www.who.int/hepatitis/publications/glob al-hepatitis-report2017/en/ [alıntı 2017 Jun 19]
13. Ertekin V, Selimoğlu MA, Alp H. Erzurum’da 6-17 yaş grubu çocuklarda HBV infeksiyonu prevalansı çalışması sırasında saptanan atipik serolojik profiller. Viral Hepatit Derg.2003; 8: 60-3.
14. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol.2007; 46: 160-70.
15. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
16. Da Silva EF, Mazo DF, Oliveira CP, Medeiros RP, Carrilho FJ, Pessôa MG. HAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a tertiary care Center in São Paulo, Brazil. Ann Hepatol. 2016; 15(5): 691-5
17. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008; 23(4): 512-20.
18. Erden S, Büyüközturk S, Çalangu S ve et al. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract 2003;12: 184-8.
19. Tozun N, Ozdoğan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalance of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6.
20. Çabalak M, Bal T, Ocak S. Hepatitis Serology in Patients Receiving Immunosuppressive Treatment.Harran Üniversitesi Tıp Fakültesi Dergisi (Journal of Harran University Medical Faculty) 2020;17(1):70-73
21. Demirtürk N, Demirdal T, Altındiş M, Asçı Z. Hepatit C virüsü ile enfekte hastalarda hepatit A ve hepatit B virüs serolojileri. Ege Tıp Dergisi 2007;46:97-100.
22. Aygen B, Çelen MK, Köksal İ, Tosun S, Karabay O,Yamazhan T ve et al. The prevalence and epidemiological characteristics of hepatitis B virus and hepatitis C virus coinfection in Turkey. Turkiye Klinikleri J Med Sci, 2013; 33 (5): 1245-49.
23. Stroffolini T, et al. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease 2019; 51:434–437
24. Chen G.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.Hepatology 2017;66:1
25. Tyson GL, Kramer JR, Duan Z, Davila JA. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.Hepatology. 2013; 58: 538 – 45
26. Yu G, Chi X, Wu R, et al. Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population. PLoS One. 2015; 10(9): e0139015.
27. Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH et al. Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection. Medicine (Baltimore). 2016; 95: e2995
28. Mitre HP, Mendonça JS. Co-infection with hepatitis B virus and hepatitis C virus. Braz J Infect Dis 2007;1:33-5.
29. Karadağ F Hepatit C virüsü ile enfekte hastalarda Hepatit B seroprevalansının araştırılması Türk Hijyen ve Deneysel Biyoloji Dergisi 2017,74(4): 287-292.
30. Tahmaz A, et al. "Kronik Hepatit C Enfeksiyonlu Hastalarda İzole Hepatit B Kor Antikoru (Anti-Hbc Igg) Seropozitifliğinin Araştırılması," Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 2019; 14(3):119-123
31. Dağlı Ö, Kasapoğlu Aksoy M. Ankilozan spondilitli hastalarda hepatit B ve hepatit C enfeksiyon prevalansı. Ortadoğu Tıp Derg, 2018;10(3):297-301.

Hepatit C Virüsü ile Enfekte Hastalarda Anti HBs, HBsAg Pozitifliğinin Araştırılması

Year 2021, Volume: 6 Issue: 2, 90 - 96, 30.06.2021

Feray Ferda Şenol İlkay Bahçeci Nuray Arslan Özlem Aytaç Pinar Öner Arzu Şenol Zülal Aşcı Toraman

Abstract

HCV Virüsü ile Enfekte Hastalarda; HBsAg, Anti HBs ve AntiHBc IgG Pozitifliğinin Araştırılması

ÖZET
Amaç: Hepatit C virüsüne bağlı (HCV) enfeksiyon ülkemizde ve tüm dünyada önemi her geçen artan ciddi halk sağlığı problemlerinden biridir. Hastalığın önlenmesine yönelik HCV’ye karşı henüz etkili bir aşı bulunmazken Hepatit B virüs (HBV)’ne karşı rutin aşı uygulaması mevcuttur. Bundan dolayı HCV tanısı alanların, HBV açısından araştırılması ve seropozitiflik yoksa mutlaka aşı programına dahil edilmesi tavsiye edilmektedir. Bu çalışmada poliklinik ve servislerden başvuran, HCV ile enfekte hastaların hepatit B yüzey antijeni ( HBsAg) ve hepatit B yüzey antikoru (Anti-HBS) seroprevalansı ile izole AntiHBc IgG pozitifliğini saptayarak, seronegatif kişilerin tespit edilmesi amaçlanmıştır.

Gereç ve Yöntem: Çalışmada; Ekim 2018 - Eylül 2020 tarihlerinde hastaneye başvuran ve kronik HCV tanısı alan hastaların dosyası retrospektif olarak incelenmiştir. HBV tespitine yönelik markerlardan HBsAg, Anti-HBs ve Anti-HBc IgG tespiti yapılan ve sonuçları taranan hastalar çalışmaya dahil edilmiştir.

Bulgular: Çalışmaya katılan toplam 821 vakanın, 305 (%37,15)’i kadın olup, 516 (%62,85)’sı erkekdi ve yaş ortalaması 47±11.5 idi. HCV pozitif hastaların HBsAg değeri, Anti-HBs pozitifliği ve izole Anti-HBc IgG seropozitifliği sırasıyla 17(%2,07), 231(%28,13), 75(%9,13) idi.

Sonuç: Kronik HCV’li hastalarda HBsAg, HBs antikor pozitifliği, izole Anti-HBc IgG seropozitifliği ulusal ve uluslararası verileri ile parallel olarak saptanmıştır. Bu sonuçlar doğrultusunda HCV tanısı alan her hastanın HBV enfeksiyonu açısından taranıp seronegatif hastaların koenfeksiyon gelişmesini önlemek amacıyla mutlaka aşılama programına dahil edilmesi gerektiği sonucuna varılmıştır.

Anahtar Kelimeler: AntiHBS, HBV, HCV, seroprevalans

Keywords

HBV, AntiHBV, HCV, seropozitiflik

Project Number

References

1. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59 (3):18-27.
2. Dilek AR, Sahin K, Bahceci I, Dilek N. The different distribution of hepatitis C virus genotypes in Eastern Black Sea region of Turkey - J Microb Biochem Technol, 2013;5 (4):92-4
3. World Health Organization (WHO). Global hepatitis report 2017-WHO 2018.
4. Degenhardt L, Peacock A, Colledge S, Leung J, Vickerman P, Stone J, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal 2017; 5(12): e1192-e1207.
5. Bahçeci I, Yıldız I. HIV Seropositivity in Patients Admitted to Our Hospital: Six Year Evaluation. Duzce Medical Journal. 2021; 23(1): 25-29.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007; 132 (7): 2557-76.
7. Shepard CW, Finelli L, Alter MJ .Global epidemiology of hepatitis C virus infections. Lancet Infect Dis, 2005; 5 (9): 558 -67.
8. Sünbül M. HCV İnfeksiyonunun Epidemiyolojisi ve Korunma. Ed : Tabak F,Balık İ, Tekeli E. Viral Hepatit 2007. 1st ed. İstanbul Tıp Kitabevi, 2007: 208-19.
9. Taşyaran MA. Hepatit B virüs infeksiyonunda klinik.Viral Hepatit 2007’de. Ed. Tabak F, Tekeli E, Balık İ. 1.Baskı. İstanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;118-22.
10. Özdemir D, Kurt H. Hepatit B virüsü enfeksiyonlarının epidemiyolojisi. Viral Hepatit 2007’de. Ed. Tabak F, Tekeli E,Balık İ. 1. baskı. istanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;108-7.
11. Mıstık R. Türkiye’de viral hepatit epidemiyolojisi yayınlarının irdelenmesi. Viral Hepatit 2007’de. Ed. Tabak F, Balık İ, Tekeli E. 1.baskı. istanbul, Viral Hepatitle Savaşım Derneği Yayını, 2007;10-50.
12. Global hepatit raporu. Cenevre: Dünya Sağlık Örgütü. Erişim: http://www.who.int/hepatitis/publications/glob al-hepatitis-report2017/en/ [alıntı 2017 Jun 19]
13. Ertekin V, Selimoğlu MA, Alp H. Erzurum’da 6-17 yaş grubu çocuklarda HBV infeksiyonu prevalansı çalışması sırasında saptanan atipik serolojik profiller. Viral Hepatit Derg.2003; 8: 60-3.
14. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol.2007; 46: 160-70.
15. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
16. Da Silva EF, Mazo DF, Oliveira CP, Medeiros RP, Carrilho FJ, Pessôa MG. HAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a tertiary care Center in São Paulo, Brazil. Ann Hepatol. 2016; 15(5): 691-5
17. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008; 23(4): 512-20.
18. Erden S, Büyüközturk S, Çalangu S ve et al. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract 2003;12: 184-8.
19. Tozun N, Ozdoğan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalance of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6.
20. Çabalak M, Bal T, Ocak S. Hepatitis Serology in Patients Receiving Immunosuppressive Treatment.Harran Üniversitesi Tıp Fakültesi Dergisi (Journal of Harran University Medical Faculty) 2020;17(1):70-73
21. Demirtürk N, Demirdal T, Altındiş M, Asçı Z. Hepatit C virüsü ile enfekte hastalarda hepatit A ve hepatit B virüs serolojileri. Ege Tıp Dergisi 2007;46:97-100.
22. Aygen B, Çelen MK, Köksal İ, Tosun S, Karabay O,Yamazhan T ve et al. The prevalence and epidemiological characteristics of hepatitis B virus and hepatitis C virus coinfection in Turkey. Turkiye Klinikleri J Med Sci, 2013; 33 (5): 1245-49.
23. Stroffolini T, et al. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease 2019; 51:434–437
24. Chen G.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.Hepatology 2017;66:1
25. Tyson GL, Kramer JR, Duan Z, Davila JA. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.Hepatology. 2013; 58: 538 – 45
26. Yu G, Chi X, Wu R, et al. Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population. PLoS One. 2015; 10(9): e0139015.
27. Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH et al. Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection. Medicine (Baltimore). 2016; 95: e2995
28. Mitre HP, Mendonça JS. Co-infection with hepatitis B virus and hepatitis C virus. Braz J Infect Dis 2007;1:33-5.
29. Karadağ F Hepatit C virüsü ile enfekte hastalarda Hepatit B seroprevalansının araştırılması Türk Hijyen ve Deneysel Biyoloji Dergisi 2017,74(4): 287-292.
30. Tahmaz A, et al. "Kronik Hepatit C Enfeksiyonlu Hastalarda İzole Hepatit B Kor Antikoru (Anti-Hbc Igg) Seropozitifliğinin Araştırılması," Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 2019; 14(3):119-123
31. Dağlı Ö, Kasapoğlu Aksoy M. Ankilozan spondilitli hastalarda hepatit B ve hepatit C enfeksiyon prevalansı. Ortadoğu Tıp Derg, 2018;10(3):297-301.

There are 31 citations in total.

Details

Primary Language	Turkish
Subjects	Internal Diseases
Journal Section	Research Articles
Authors	Feray Ferda Şenol 0000-0003-4705-5757 İlkay Bahçeci 0000-0003-3662-1629 Nuray Arslan 0000-0002-5893-1452 Özlem Aytaç 0000-0002-3305-6284 Pinar Öner 0000-0001-9592-5986 Arzu Şenol 0000-0002-8537-0195 Zülal Aşcı Toraman 0000-0001-5202-8564
Project Number	-
Publication Date	June 30, 2021
Published in Issue	Year 2021 Volume: 6 Issue: 2

Cite

APA	Şenol, F. F., Bahçeci, İ., Arslan, N., Aytaç, Ö., et al. (2021). Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus. Journal of Immunology and Clinical Microbiology, 6(2), 90-96.
AMA	Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, Şenol A, Aşcı Toraman Z. Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus. J Immunol Clin Microbiol. June 2021;6(2):90-96.
Chicago	Şenol, Feray Ferda, İlkay Bahçeci, Nuray Arslan, Özlem Aytaç, Pinar Öner, Arzu Şenol, and Zülal Aşcı Toraman. “ HBsAg Positivity in Patients Infected With Hepatitis C Virus”. Journal of Immunology and Clinical Microbiology 6, no. 2 (June 2021): 90-96.
EndNote	Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, Şenol A, Aşcı Toraman Z (June 1, 2021) Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus. Journal of Immunology and Clinical Microbiology 6 2 90–96.
IEEE	F. F. Şenol, “ HBsAg Positivity in Patients Infected with Hepatitis C Virus”., J Immunol Clin Microbiol, vol. 6, no. 2, pp. 90–96, 2021.
ISNAD	Şenol, Feray Ferda et al. “ HBsAg Positivity in Patients Infected With Hepatitis C Virus”. Journal of Immunology and Clinical Microbiology 6/2 (June 2021), 90-96.
JAMA	Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, Şenol A, Aşcı Toraman Z. Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus. J Immunol Clin Microbiol. 2021;6:90–96.
MLA	Şenol, Feray Ferda et al. “ HBsAg Positivity in Patients Infected With Hepatitis C Virus”. Journal of Immunology and Clinical Microbiology, vol. 6, no. 2, 2021, pp. 90-96.
Vancouver	Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, Şenol A, Aşcı Toraman Z. Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus. J Immunol Clin Microbiol. 2021;6(2):90-6.

Article Files

Full Text

Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

JICM is a product of QMEL® medicine & publishing